Skip to content

A comparative study on the efficacy of desugumab and zoledronic acid in the treatment of newly diagnosed postmenopausal osteoporosis patients with type 2 diabetes mellitus

A comparative study on the efficacy of desugumab and zoledronic acid in the treatment of newly diagnosed postmenopausal osteoporosis patients with type 2 diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106752
Enrollment
Unknown
Registered
2025-07-29
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis and Type 2 diabetes

Interventions

Deslumab group:Subcutaneous injection of deslumab 60mg every six months
Zoledronic acid group:Intravenous infusion of zoledronic acid 5mg per year

Sponsors

The First People’s Hospital of Longquanyi District Chengdu, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Postmenopausal women, aged 50-70 years; 2. Type 2 diabetes mellitus; 3. It meets the diagnostic criteria for osteoporosis in the guidelines for the diagnosis and treatment of primary osteoporosis, that is, it meets at least one of the following three criteria: (1) The T value of the bone mineral density of the axial bone (lumbar spine 1-4, femoral neck or total hip) or 1/3 of the distal radius measured by DXA is <= -2.5, (2) Fragile fractures of the hip or vertebral body, (3) The bone mineral density is -2.5<T value<-1.0, combined with brittle fractures of the proximal humerus, pelvis, or distal forearm; 4. Previous diagnosis or new diagnosis of osteoporosis, but no anti-osteoporosis treatment; 5. Did not take glucocorticoid treatment within half a year; 6. The patient was conscious and had no mental illness.

Exclusion criteria

Exclusion criteria: 1. Combined with other diseases that seriously affect bone metabolism, such as hyperparathyroidism or hypoparathyroidism, hyperthyroidism or hypothyroidism; 2. Patients with severe heart, liver, and lung dysfunction; 3. Renal function impairment (estimated glomerular filtration rate <= 60 ml/min/1.73m^2); 4. Hypercalcemia or hypocalcemia; 5. Allergic to the study drug.

Design outcomes

Primary

MeasureTime frame
Bone mineral density;Beta-CrossLaps (ß-CTx);Blood electrolytes;Renal function ;24-hour urine electrolytes;Pain score ;Short Physical Performance Battery (SPPB) score;

Secondary

MeasureTime frame
Markers of bone metabolism;

Countries

China

Contacts

Public ContactYing Jixiang

The First People’s Hospital of Longquanyi District Chengdu, China

810438897@qq.com+86 135 4128 4949

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026